Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
- DOI
- 10.1007/s10198-023-01639-x
- Published
- 2024 Aug
- Container
- The European journal of health economics : HEPAC : health economics in prevention and care
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10198-023-01639-x,
title = {Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.},
author = {Michaeli DT and Michaeli T and Albers S and Boch T and Michaeli JC},
year = {2024},
journal = {The European journal of health economics : HEPAC : health economics in prevention and care},
doi = {10.1007/s10198-023-01639-x},
url = {https://doi.org/10.1007/s10198-023-01639-x}
}RIS
TY - JOUR TI - Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. AU - Michaeli DT AU - Michaeli T AU - Albers S AU - Boch T AU - Michaeli JC PY - 2024 JO - The European journal of health economics : HEPAC : health economics in prevention and care DO - 10.1007/s10198-023-01639-x UR - https://doi.org/10.1007/s10198-023-01639-x ER -
APA
DT, M., T, M., S, A., T, B., & JC, M. (2024). Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.. The European journal of health economics : HEPAC : health economics in prevention and care. https://doi.org/10.1007/s10198-023-01639-x
Source records
- pubmed · retrieved 2026-09-26T22:43:56.907Z